Cargando…

NLRP3: A Novel Mediator in Cardiovascular Disease

Cardiovascular disease is a major cause of death worldwide. Inflammasome infiltration has been identified to play a central role in the pathological progression of certain cardiovascular diseases, such as vascular damage spanning atherosclerosis, aneurysm, or arteritis; ischemic heart disease; and o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Wenyi, Chen, Chunyuan, Chen, Zhiheng, Liu, Lin, Jiang, Jie, Wu, Zhixiang, Zhao, Mingyi, Chen, Yanfang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911339/ https://www.ncbi.nlm.nih.gov/pubmed/29850631 http://dx.doi.org/10.1155/2018/5702103

Ejemplares similares

How Hippo Signaling Pathway Modulates Cardiovascular Development and Diseases
por: Zhou, Wenyi, et al.
Publicado: (2018)

The role of mitochondria-associated membranes mediated ROS on NLRP3 inflammasome in cardiovascular diseases
por: Zhao, Jiahao, et al.
Publicado: (2022)

NLRP3 Inflammasome—A Key Player in Antiviral Responses
por: Zhao, Chunyuan, et al.
Publicado: (2020)

UAF1 deubiquitinase complexes facilitate NLRP3 inflammasome activation by promoting NLRP3 expression
por: Song, Hui, et al.
Publicado: (2020)

Implication of Gut Microbiota in Cardiovascular Diseases
por: Zhou, Wenyi, et al.
Publicado: (2020)

NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases
por: Mezzaroma, Eleonora, et al.
Publicado: (2021)

NLRP3 Inflammasome and Its Central Role in the Cardiovascular Diseases
por: Tong, Yeqing, et al.
Publicado: (2020)

NLRP3 inflammasome: The rising star in cardiovascular diseases
por: Zheng, Yidan, et al.
Publicado: (2022)

NLRP3 inflammasome, an immune‐inflammatory target in pathogenesis and treatment of cardiovascular diseases
por: Wang, Yucheng, et al.
Publicado: (2020)

TRIM28 SUMOylates and stabilizes NLRP3 to facilitate inflammasome activation
por: Qin, Ying, et al.
Publicado: (2021)

Heparin-Binding Protein: A Novel Biomarker Linking Four Different Cardiovascular Diseases
por: Cai, Yufeng, et al.
Publicado: (2020)

Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer
por: Ju, Mingyi, et al.
Publicado: (2020)

Regulatory Mechanisms of the NLRP3 Inflammasome, a Novel Immune-Inflammatory Marker in Cardiovascular Diseases
por: An, Na, et al.
Publicado: (2019)

Posttranslational ISGylation of NLRP3 by HERC enzymes facilitates inflammasome activation in models of inflammation
por: Qin, Ying, et al.
Publicado: (2023)

Activation of Platelet NLRP3 Inflammasome in Crohn’s Disease
por: Zhang, Ge, et al.
Publicado: (2021)

Costunolide covalently targets NACHT domain of NLRP3 to inhibit inflammasome activation and alleviate NLRP3-driven inflammatory diseases
por: Xu, Haowen, et al.
Publicado: (2023)

NLRP3-mediated pyroptosis in diabetic nephropathy
por: Wan, Jiayi, et al.
Publicado: (2022)

Corilagin Restrains NLRP3 Inflammasome Activation and Pyroptosis through the ROS/TXNIP/NLRP3 Pathway to Prevent Inflammation
por: Luo, Tianyu, et al.
Publicado: (2022)

The Role of NLRP3 Inflammasome in Alzheimer’s Disease and Potential Therapeutic Targets
por: Liang, Tao, et al.
Publicado: (2022)

Huoxue Qianyang Qutan recipe attenuates cardiac fibrosis by inhibiting the NLRP3 inflammasome signalling pathway in obese hypertensive rats
por: Lu, Bo, et al.
Publicado: (2021)

A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseases
por: Docherty, Callum AH, et al.
Publicado: (2023)

Role of mitochondrial stress and the NLRP3 inflammasome in lung diseases
por: Chen, Yonghu, et al.
Publicado: (2023)

SUMO-mediated regulation of NLRP3 modulates inflammasome activity
por: Barry, Rachael, et al.
Publicado: (2018)

Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases
por: Huang, Yi, et al.
Publicado: (2018)

Electroacupuncture Ameliorates Neuroinflammation-Mediated Cognitive Deficits through Inhibition of NLRP3 in Presenilin1/2 Conditional Double Knockout Mice
por: Li, Kun, et al.
Publicado: (2021)

Targeting NLRP3-Mediated Neuroinflammation in Alzheimer’s Disease Treatment
por: Barczuk, Julia, et al.
Publicado: (2022)

Exosomes Regulate NLRP3 Inflammasome in Diseases
por: Li, Zhangwang, et al.
Publicado: (2022)

Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19
por: Yong, Yuan-Yuan, et al.
Publicado: (2022)

Downregulation of the NLRP3/Caspse-1 Pathway Ameliorates Ketamine-Induced Liver Injury and Inflammation in Developing Rats
por: Chen, Xinzhang, et al.
Publicado: (2022)

A gain-of-function NLRP3 3′-UTR polymorphism causes miR-146a-mediated suppression of NLRP3 expression and confers protection against sepsis progression
por: Lu, Furong, et al.
Publicado: (2021)

VSIG4 mediates transcriptional inhibition of Nlrp3 and Il-1β in macrophages
por: Huang, Xiaoyong, et al.
Publicado: (2019)

ER Stress Activates the NLRP3 Inflammasome: A Novel Mechanism of Atherosclerosis
por: Chen, Xinnong, et al.
Publicado: (2019)

Enhanced Autolysosomal Function Ameliorates the Inflammatory Response Mediated by the NLRP3 Inflammasome in Alzheimer’s Disease
por: Zhou, Wen, et al.
Publicado: (2021)

High glucose mediates NLRP3 inflammasome activation via upregulation of ELF3 expression
por: Wang, Jing, et al.
Publicado: (2020)

Ginsenoside compound K alleviates osteoarthritis by inhibiting NLRP3‑mediated pyroptosis
por: Li, Yuguo, et al.
Publicado: (2023)

The role of activated NLRP3 inflammatory body in acute kidney injury in rats caused by sepsis and NLRP3-TXNIP signaling pathway
por: Deng, Huanghao, et al.
Publicado: (2020)

Immunoproteasome modulates NLRP3 inflammasome‐mediated neuroinflammation under cerebral ischaemia and reperfusion conditions
por: Chen, Xingyong, et al.
Publicado: (2021)

Targeting microglial NLRP3 in the SNc region as a promising disease‐modifying therapy for Parkinson's disease
por: Qiao, Chen, et al.
Publicado: (2022)

Vitamin D Receptor Inhibits NLRP3 Activation by Impeding Its BRCC3-Mediated Deubiquitination
por: Rao, Zebing, et al.
Publicado: (2019)

Bibliometric evaluation of 2020–2022 publications on COVID-19-related cardiovascular disease
por: Chen, Yiru, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sv4s2j29ntffgt9c1sbgujqq8i